Induced Stem Cells Show Genetic Abnormalities Not Found in Embryonic Stem Cells
|
By LabMedica International staff writers Posted on 15 Jul 2014 |

Image: Scanning electron micrograph of cultured human neuron from induced pluripotent stem cell (Photo courtesy of the University of California, San Diego).
All stem cells are not created equal: genomic evaluation revealed that the genome of stem cells generated from adult cells (induced pluripotent stem cells or iPS cells) differed considerably from that of "gold standard" human embryonic stem cells (ES cells).
Human pluripotent stem cells hold potential for regenerative medicine, but available cell types have significant limitations. Although ES cells from in vitro fertilized embryos (IVF ES cells) represent the "gold standard," they are genetically distinct from likely transplant recipients, and their use is compromised by ethical and logistical considerations. While autologous iPS cells are freely obtainable, they are prone to epigenetic and transcriptional aberrations.
A team of researchers from the University of California, San Diego (USA), Oregon Health & Science University (Portland, USA) and the Salk Institute for Biological Studies (La Jolla, CA, USA) cooperated to perform a study to determine whether abnormalities found in iPS cells were intrinsic to somatic cell reprogramming or secondary to the reprogramming method. To this end, they prepared genetically matched sets of human IVF ES cells (four lines), iPS cells (seven lines), and two lines of nuclear transfer ES cells (NT ES cells) derived by somatic cell nuclear transfer (SCNT). The 13 cell lines were examined by genome-wide analyses.
Results published in the July 2, 2014, online edition of the journal Nature revealed critical differences in the genomes of stem cells created with the three methods. Specifically, DNA methylation and gene expression patterns in nuclear transfer ES cells more closely resembled those of ES cells than did iPS cells, which revealed alterations apparently caused by the reprogramming process.
“The nuclear transfer ES cells are much more similar to real ES cells than the iPS cells,” said co-senior author Dr. Louise Laurent, assistant professor of reproductive medicine at the University of California, San Diego. “They are more completely reprogrammed and have fewer alterations in gene expression and DNA methylation levels that are attributable to the reprogramming process itself. Our results have shown that widely used iPS cell reprogramming methods make cells that are similar to standard ES cells in broad strokes, but there are important differences when you look really closely. By using the egg cell to do the job, we can get much closer to the real thing. However, not only is nuclear transfer technically difficult, but federal funds cannot be used in experiments involving this procedure. If we can figure out what factors in the egg drive the reprogramming process, maybe we can design a better iPS cell reprogramming method.”
Related Links:
University of California, San Diego
Oregon Health & Science University
Salk Institute for Biological Studies
Human pluripotent stem cells hold potential for regenerative medicine, but available cell types have significant limitations. Although ES cells from in vitro fertilized embryos (IVF ES cells) represent the "gold standard," they are genetically distinct from likely transplant recipients, and their use is compromised by ethical and logistical considerations. While autologous iPS cells are freely obtainable, they are prone to epigenetic and transcriptional aberrations.
A team of researchers from the University of California, San Diego (USA), Oregon Health & Science University (Portland, USA) and the Salk Institute for Biological Studies (La Jolla, CA, USA) cooperated to perform a study to determine whether abnormalities found in iPS cells were intrinsic to somatic cell reprogramming or secondary to the reprogramming method. To this end, they prepared genetically matched sets of human IVF ES cells (four lines), iPS cells (seven lines), and two lines of nuclear transfer ES cells (NT ES cells) derived by somatic cell nuclear transfer (SCNT). The 13 cell lines were examined by genome-wide analyses.
Results published in the July 2, 2014, online edition of the journal Nature revealed critical differences in the genomes of stem cells created with the three methods. Specifically, DNA methylation and gene expression patterns in nuclear transfer ES cells more closely resembled those of ES cells than did iPS cells, which revealed alterations apparently caused by the reprogramming process.
“The nuclear transfer ES cells are much more similar to real ES cells than the iPS cells,” said co-senior author Dr. Louise Laurent, assistant professor of reproductive medicine at the University of California, San Diego. “They are more completely reprogrammed and have fewer alterations in gene expression and DNA methylation levels that are attributable to the reprogramming process itself. Our results have shown that widely used iPS cell reprogramming methods make cells that are similar to standard ES cells in broad strokes, but there are important differences when you look really closely. By using the egg cell to do the job, we can get much closer to the real thing. However, not only is nuclear transfer technically difficult, but federal funds cannot be used in experiments involving this procedure. If we can figure out what factors in the egg drive the reprogramming process, maybe we can design a better iPS cell reprogramming method.”
Related Links:
University of California, San Diego
Oregon Health & Science University
Salk Institute for Biological Studies
Latest BioResearch News
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
- Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
Channels
Clinical Chemistry
view channel
Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read moreMolecular Diagnostics
view channel
Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read moreMicrobiology
view channel
Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
PCR amplifies DNA to enable highly accurate testing, but its reliance on complex, expensive laboratory analyzers has traditionally kept many workflows in centralized settings. A new personal DNA analyzer... Read more
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more







